Search Results - "KAKOLYRIS, S"

Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG) by Mavroudis, D., Saloustros, E., Malamos, N., Kakolyris, S., Boukovinas, I., Papakotoulas, P., Kentepozidis, N., Ziras, N., Georgoulias, V.

“…Adjuvant trastuzumab in combination with chemotherapy improves survival of women with HER2-positive early breast cancer. In this study, we compared 12 versus 6…”
Get full text

Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project by Souglakos, J., Boukovinas, I., Kakolyris, S., Xynogalos, S., Ziras, N., Athanasiadis, A., Androulakis, N., Christopoulou, A., Vaslamatzis, M., Ardavanis, A., Emmanouilides, C., Bompolaki, I., Kourousis, C., Makrantonakis, P., Christofyllakis, C., Athanasiadis, E., Kentepozidis, N., Karampeazis, A., Katopodi, U., Anagnosopoulos, A., Papadopoulos, G., Prinarakis, E., Kalisperi, A., Mavroudis, D., Georgoulias, V.

“…The International Duration Evaluation of Adjuvant Chemotherapy (IDEA) aimed to investigate whether a 3 months (3M) of oxaliplatin/fluoropyrimidine-based…”
Get full text

Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients by Balgkouranidou, I, Matthaios, D, Karayiannakis, A, Bolanaki, H, Michailidis, P, Xenidis, N, Amarantidis, K, Chelis, L, Trypsianis, G, Chatzaki, E, Lianidou, E S, Kakolyris, S

“…Gastric carcinogenesis is a multistep process including not only genetic mutations but also epigenetic alterations. The best known and more frequent epigenetic…”
Get more information

Evaluation of artificial time series microarray data for dynamic gene regulatory network inference by Xenitidis, P., Seimenis, I., Kakolyris, S., Adamopoulos, A.

“…•The influence of a number of factors on the inference of a gene regulatory network using microarray data was examined.•The amount of information in microarray…”
Get full text

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG) by Souglakos, J, Androulakis, N, Syrigos, K, Polyzos, A, Ziras, N, Athanasiadis, A, Kakolyris, S, Tsousis, S, Kouroussis, Ch, Vamvakas, L, Kalykaki, A, Samonis, G, Mavroudis, D, Georgoulias, V

“…To compare the efficacy and toxicity of oxaliplatin (L-OHP) in combination with irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) (FOLFOXIRI) vs…”
Get full text

Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer by Balgkouranidou, I, Chimonidou, M, Milaki, G, Tsarouxa, E G, Kakolyris, S, Welch, D R, Georgoulias, V, Lianidou, E S

“…Background: Breast-cancer metastasis suppressor 1 ( BRMS1 ) gene encodes for a predominantly nuclear protein that differentially regulates the expression of…”
Get full text

Corrigendum to Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG): Annals of Oncology, Volume 26, Issue 7, July 2015, Pages 1333–1340 by Mavroudis, D., Saloustros, E., Malamos, N., Kakolyris, S., Boukovinas, I., Papakotoulas, P., Kentepozidis, N., Ziras, N., Georgoulias, V.

Get full text

Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG) by Mavroudis, D., Matikas, A., Malamos, N., Papakotoulas, P., Kakolyris, S., Boukovinas, I., Athanasiadis, A., Kentepozidis, N., Ziras, N., Katsaounis, P., Saloustros, E., Georgoulias, V.

“…Sequential administration of anthracycline and taxane is the current standard of care adjuvant regimen for node-positive early breast cancer. Due to long-term…”
Get full text

H2AX a Promising Biomarker for Lung Cancer: A Review by Matthaios, D., Hountis, P., Karakitsos, P., Bouros, D., Kakolyris, S.

“…Histone's H2A variant (H2AX) phosphorylation is an early indicator of DNA double-strand breaks formation and DNA damage response. Thus, it may act as a novel…”
Get full text

Molecular Detection of Cytokeratin-19–Positive Cells in the Peripheral Blood of Patients With Operable Breast Cancer: Evaluation of Their Prognostic Significance by STATHOPOULOU, A, VLACHONIKOLIS, I, REPPA, D, GEORGOULIAS, V, MAVROUDIS, D, PERRAKI, M, KOUROUSSIS, Ch, APOSTOLAKI, S, MALAMOS, N, KAKOLYRIS, S, KOTSAKIS, A, XENIDIS, N

“…To evaluate the prognostic significance of molecular detection of cytokeratin 19 (CK-19) mRNA-positive cells by nested reverse transcriptase polymerase chain…”
Get full text

Prognostic significance of SOX17 and WNT5a promoter methylation status in circulating cell-free DNA metastatic colorectal cancer patients by Vagionas, A, Balgkouranidou, I, Koukaki, T, Biziota, E, Amarantidis, K, Kakolyris, S, Xenidis, N

“…Carcinogenesis of colorectal cancer is a process involving genetic mutations and epigenetic alterations in its multiple phases. The most considerable…”
Get full text

Molecular pathogenesis of pancreatic cancer and clinical perspectives by Matthaios, D, Zarogoulidis, P, Balgouranidou, I, Chatzaki, E, Kakolyris, S

“…Pancreatic cancer remains stubbornly resistant to many key cytotoxic chemotherapeutic agents and novel targeted therapies. The molecular heterogeneity of this…”
Get more information

Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC) by Souglakos, J, Ziras, N, Kakolyris, S, Boukovinas, I, Kentepozidis, N, Makrantonakis, P, Xynogalos, S, Christophyllakis, Ch, Kouroussis, Ch, Vamvakas, L, Georgoulias, V, Polyzos, A

“…Background: To compare the efficacy and safety of CAPIRI+bevacizumab (Bev) in comparison with FOLFIRI+Bev as first-line treatment for patients with metastatic…”
Get full text

Concentration of circulating tumour DNA in patients with metastatic gastric cancer and its prognostic significance by Karamitrousis, E., Balgkouranidou, I., Xenidis, N., Amarantidis, K., Biziota, E., Koukaki, T., Kakolyris, S.

“…Gastric cancer is one of the most common cancers worldwide. The amount of cell-free DNA (cfDNA) in the blood of patients with gastric cancer was found to be…”
Get full text

2388 Serum mass spectrometry analysis in hepatocellular carcinoma (HCC) patients treated with sorafenib (S) by Chelis, L, Kakolyris, S, Mimidis, K, Xenidis, N, Amarantidiss, K, Meyer, K, Roder, H

Get full text

Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer by Xenidis, N, Perraki, M, Apostolaki, S, Agelaki, S, Kalbakis, K, Vardakis, N, Kalykaki, A, Xyrafas, A, Kakolyris, S, Mavroudis, D, Georgoulias, V

“…Background: To determine the effect of adjuvant taxane-free and taxane-based chemotherapy regimens on the elimination of circulating tumour cells (CTCs) in…”
Get full text

H2AX and lung cancer: Is it the Ariadne's thread? by Matthaios, D., Bouros, D., Kakolyris, S.

Get full text

Clinical relevance of circulating CK-19 mRNA-positive cells detected during the adjuvant tamoxifen treatment in patients with early breast cancer by Xenidis, N., Markos, V., Apostolaki, S., Perraki, M., Pallis, A., Sfakiotaki, G., Papadatos-Pastos, D., Kalmanti, L., Kafousi, M., Stathopoulos, E., Kakolyris, S., Mavroudis, D., Georgoulias, V.

“…Background: The purpose of this study was to evaluate the effect of adjuvant treatment with tamoxifen on the CK-19 mRNA+ cells in patients with early-stage…”
Get full text

Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer by Mavroudis, D., Papakotoulas, P., Ardavanis, A., Syrigos, K., Kakolyris, S., Ziras, N., Kouroussis, C., Malamos, N., Polyzos, A., Christophyllakis, C., Kentepozidis, N., Georgoulias, V.

“…Background: The purpose of this study was to compare docetaxel plus epirubicin versus docetaxel plus capecitabine combinations as front-line treatment in women…”
Get full text

Triplet Combination With Irinotecan Plus Oxaliplatin Plus Continuous-Infusion Fluorouracil and Leucovorin as First-Line Treatment in Metastatic Colorectal Cancer: A Multicenter Phase II Trial by SOUGLAKOS, J, MAVROUDIS, D, SAMONIS, G, GEORGOULIAS, V, KAKOLYRIS, S, KOUROUSIS, Ch, VARDAKIS, N, ANDROULAKIS, N, AGELAKI, S, KALBAKIS, K, TSETIS, D, ATHANASIADIS, N

“…To evaluate the efficacy and tolerance of irinotecan (CPT-11) in combination with oxaliplatin (L-OHP) plus fluorouracil (5-FU)/leucovorin (LV) (de Gramont…”
Get full text